COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.90 -0.05 (-0.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Mind Medicine, Allied Among Top Psychedelic Movers Of Today ↗

February 02, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17

Via Benzinga

New Psychedelics ETF Launches On NYSE Arca ↗

February 02, 2022

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...

Via Benzinga

Mindset Pharma, Allied Among Top Psychedelic Movers Of Today ↗

February 01, 2022

GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 15.70% at $0.69

Via Benzinga

ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today ↗

January 31, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33

Via Benzinga

Has A Sugar Daddy Emerged In The Psychedelic Drug Industry? ↗

January 31, 2022

One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry.

Via Talk Markets

The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January ↗

January 30, 2022

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.

Via Talk Markets

Psychedelic Stock Gainers And Losers From January 28, 2022 ↗

January 28, 2022

GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57

Via Benzinga

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today ↗

January 27, 2022

GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49

Via Benzinga

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today ↗

January 26, 2022

GAINERS: Small Pharma (OTC:

Via Benzinga

Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today ↗

January 25, 2022

GAINERS: Mind Medicine (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From January 24, 2022 ↗

January 24, 2022

GAINERS: Field Trip Health (NASDAQ:

Via Benzinga

Psyched: Eleusis To Go Public Via Merger, New Psychedelics Bills In Utah, Virginia, Kansas And Missouri ↗

January 24, 2022

Psychedelics Legalization Gains Momentum Around The Country: Bills Introduced In Utah, Virginia, Kansas And Missouri A wave of psychede...

Via Benzinga

Weekend Update: Only 2 Psychedelic Drug Stocks Are Up YTD ↗

January 23, 2022

This article updates the performances of the 16 largest capitalized clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses out of a...

Via Talk Markets

Psychedelic Stock Gainers And Losers From January 21, 2022 ↗

January 21, 2022

GAINERS: GH Research (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From January 20, 2022 ↗

January 20, 2022

GAINERS: Small Pharma (OTC:

Via Benzinga

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗

January 19, 2022

GAINERS: Revive Therapeutics (OTC:

Via Benzinga

Two-Thirds Of Physicians Say Psilocybin Therapy Can Help Treatment-Resistant Depression, New Survey Shows ↗

January 19, 2022

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:

Via Benzinga

Psilocybin and MDMA Get the Green Light for Medical Use in Canada

January 19, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of...

Via FinancialNewsMedia

Psychedelic Stock Gainers And Losers From January 18, 2022 ↗

January 18, 2022

GAINERS: Cybin (AMEX:

Via Benzinga

Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington ↗

January 10, 2022

Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA In a groundbreaking decision, the Canadian gov...

Via Benzinga

A Recap of How Psychedelics Fared in 2021

January 07, 2022

Via Investor Brand Network

Psilocybin Does Not Produce Adverse Effects On Cognition Or Emotional Function, New Study Finds ↗

January 04, 2022

A new study is shedding light on the safety profile of psilocybin, the active ingredient in so-called “magic mushrooms.&rdqu...

Via Benzinga

Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021! ↗

January 02, 2022

Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the...

Via Talk Markets

2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around? ↗

December 30, 2021

Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv...

Via Benzinga

Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD ↗

December 24, 2021

All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?

Via Talk Markets

The Year In Review For Psychedelic Drug Stocks: 2021 ↗

December 21, 2021

2021 was two different

Via Talk Markets

Why Jim Cramer Likes MGM Growth Properties ↗

December 21, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enterprise Products Partners L.P. (NYSE:

Via Benzinga

Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD ↗

December 17, 2021

A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.

Via Talk Markets

Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index ↗

December 17, 2021

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:

Via Benzinga

North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026

December 14, 2021

Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept...

Via FinancialNewsMedia

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.